Conclusion of a dispute with the National Centre for Research and Development and termination of a reserve concerning the CT-02 project

Current report no. 22/2025

Drafting date: 27.05.2025

Subject: Conclusion of a dispute with the National Centre for Research and Development and termination of a reserve concerning the CT-02 project

Legal basis: Article 17(1) MAR - confidential information.

With reference to current reports: no. 21/2023 of 6 June 2023, no. 24/2023 of 20 June 2023, No. 27/2023 of 7 July 2023 and No. 21/2025 of 16 May 2025 (“Current Reports”), the Management Board of Captor Therapeutics S.A. with its registered office in Wrocław (the “Company”) announces that the Company has decided not to appeal the decision of the National Centre for Research and Development (“NCBiR”), about which the Company informed in Current Report No. 21/2025 of 16 May 2025, and thus to terminate the dispute with NCBiR in the matter in question. Consequently, the Company will fully dissolve the provision for the liability to NCBiR, amounting to PLN 7.9 million.

In accordance with the decision issued by NCBiR, the Company has returned the PLN 4.1 million it received under the grant for the CT-02 project. The Company will also transfer approximately PLN 1.3 million as interest on the returned amount. The Company will apply for a reduction in the amount of interest, but the decision in this regard will rest with NCBiR.

As a result of the release of the provision and the above payments, the Company will report a remaining operating income of PLN 2.5 million, which will be recognised in the results for Q2 2025.

The Company intends to develop the CT-02B and CT-02S projects, which are the continuation of the CT-02 project. The Company allows both projects to be developed independently - in the event that revenues from other projects are achieved - and with a partner.